MCID: LNG064
MIFTS: 76

Lung Cancer Susceptibility 3

Categories: Rare diseases, Cancer diseases, Respiratory diseases

Aliases & Classifications for Lung Cancer Susceptibility 3

MalaCards integrated aliases for Lung Cancer Susceptibility 3:

Name: Lung Cancer Susceptibility 3 57 13 73
Lung Adenocarcinoma 38 12 53 29 6 15
Adenocarcinoma of Lung 57 12 76 44 73
Adenocarcinoma of Lung, Susceptibility to 57
Bronchogenic Lung Adenocarcinoma 12
Non-Small Cell Adenocarcinoma 73
Nonsmall Cell Adenocarcinoma 12
Adenocarcinoma Lung 55
Lncr3 57

Classifications:



External Ids:

OMIM 57 612571
Disease Ontology 12 DOID:3910
MeSH 44 C538231
NCIt 50 C27745 C3512
SNOMED-CT 68 254626006

Summaries for Lung Cancer Susceptibility 3

NIH Rare Diseases : 53 Lung adenocarcinoma is a cancer that occurs due to abnormal and uncontrolled cell growth in the lungs. It is a subtype of non-small cell lung cancer that is often diagnosed in an outer area of the lung. Early lung cancers may not be associated with any signs and symptoms. As the condition progresses, affected people can experience chest pain, a persistent cough, fatigue, coughing up blood, loss of appetite, unexplained weight loss, shortness of breath, and/or wheezing. The underlying cause of lung adenocarcinoma is generally unknown; however, risk factors for developing a lung cancer include smoking; exposure to secondhand smoke and other toxic chemicals; a family history of lung cancer; previous radiation treatment to the chest or breast; and HIV infection. Treatment varies based on the severity of the condition, the associated signs and symptoms and the affected person's overall health. It may include a combination of surgery, radiation therapy, chemotherapy, targeted therapy, and/or watchful waiting.

MalaCards based summary : Lung Cancer Susceptibility 3, also known as lung adenocarcinoma, is related to lung cancer and adenocarcinoma. An important gene associated with Lung Cancer Susceptibility 3 is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Gilotrif and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and testes, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A non-small cell lung carcinoma that derives from epithelial cells of glandular origin.

Wikipedia : 76 Adenocarcinoma of the lung (also known as pulmonary adenocarcinoma) is the most common type of lung... more...

Description from OMIM: 612571

Related Diseases for Lung Cancer Susceptibility 3

Diseases in the Lung Cancer Susceptibility 3 family:

Lung Cancer Susceptibility 1 Lung Cancer Susceptibility 4
Lung Cancer Susceptibility 5

Diseases related to Lung Cancer Susceptibility 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 165)
# Related Disease Score Top Affiliating Genes
1 lung cancer 35.0 BRAF CDK4 EGFR ERBB2 HOTAIR HRAS
2 adenocarcinoma 33.1 APC BRAF CDK4 EGFR ERBB2 FGFR3
3 squamous cell carcinoma 32.0 BRAF EGFR ERBB2 FGFR3 HOTAIR HRAS
4 gastrointestinal stromal tumor 31.6 BRAF EGFR HOTAIR TP53
5 mucinous lung adenocarcinoma 12.2
6 signet ring lung adenocarcinoma 12.1
7 colorectal cancer 11.8 APC BRAF CDK4 EGFR ERBB2 FGFR3
8 gastric adenocarcinoma 11.8 APC BRAF EGFR ERBB2 HOTAIR HRAS
9 squamous cell carcinoma, head and neck 11.8 BRAF CDK4 EGFR ERBB2 FGFR3 HOTAIR
10 pancreatic cancer 11.8 CDK4 EGFR ERBB2 HOTAIR HRAS MALAT1
11 glioblastoma 11.8 BRAF CDK4 EGFR ERBB2 HOTAIR HRAS
12 esophageal cancer 11.8 CDK4 EGFR ERBB2 HOTAIR HRAS MALAT1
13 hepatocellular carcinoma 11.8 APC CDK4 EGFR HOTAIR HRAS MALAT1
14 bladder urothelial carcinoma 11.8 BRAF ERBB2 FGFR3 HOTAIR HRAS MALAT1
15 adamantinoma of long bones 11.8 APC BRAF CDK4 EGFR ERBB2 HOTAIR
16 gastrointestinal system cancer 11.7 EGFR ERBB2 HOTAIR HRAS MALAT1 PIK3CA
17 cholangiocarcinoma 11.7 EGFR ERBB2 HRAS MALAT1 PIK3CA RAF1
18 renal cell carcinoma, papillary, 1 11.7 BRAF ERBB2 FGFR3 HRAS NRAS PIK3CA
19 skin melanoma 11.7 BRAF CDK4 ERBB2 HRAS NRAS PIK3CA
20 glioma 11.7 BRAF CDK4 EGFR ERBB2 HOTAIR MALAT1
21 prostate cancer 11.7 CDK4 EGFR ERBB2 HOTAIR HRAS MALAT1
22 nasopharyngeal carcinoma 11.7 CDK4 EGFR HOTAIR HRAS MALAT1 NRAS
23 myeloma, multiple 11.7 BRAF CDK4 FGFR3 HOTAIR HRAS MALAT1
24 endometrial cancer 11.7 BRAF CDK4 EGFR ERBB2 HOTAIR HRAS
25 ovarian cancer 11.7 BRAF CDK4 EGFR ERBB2 HOTAIR MALAT1
26 cervical cancer 11.7 ERBB2 FGFR3 HOTAIR HRAS MALAT1 PIK3CA
27 breast cancer 11.7 APC BRAF CDK4 EGFR ERBB2 HOTAIR
28 lung squamous cell carcinoma 11.7 BRAF EGFR FGFR3 HRAS MIR375 PIK3CA
29 ovarian serous cystadenocarcinoma 11.7 BRAF ERBB2 HRAS NRAS PIK3CA TP53
30 bladder cancer 11.7 CDK4 EGFR ERBB2 FGFR3 HOTAIR HRAS
31 respiratory system cancer 11.7 EGFR ERBB2 HRAS MALAT1 PIK3CA TP53
32 pancreas adenocarcinoma 11.7 EGFR ERBB2 HRAS PIK3CA SMAD4 TP53
33 cell type cancer 11.7 CDK4 EGFR ERBB2 HRAS NRAS TP53
34 thyroid cancer 11.7 APC BRAF HOTAIR HRAS MALAT1 NRAS
35 gastric cancer 11.7 APC EGFR ERBB2 HOTAIR MALAT1 PIK3CA
36 pilocytic astrocytoma 11.7 BRAF CDK4 HRAS PIK3CA RAF1 TP53
37 acneiform dermatitis 11.7 EGFR ERBB2 HRAS NRAS PIK3CA
38 adenosquamous cell lung carcinoma 11.7 EGFR ERBB2 FGFR3 HRAS PIK3CA
39 malignant ovarian surface epithelial-stromal neoplasm 11.7 EGFR ERBB2 HRAS PIK3CA TP53
40 ovary epithelial cancer 11.7 EGFR ERBB2 HRAS PIK3CA TP53
41 brain cancer 11.7 BRAF EGFR HRAS NRAS PIK3CA TP53
42 female reproductive organ cancer 11.7 EGFR ERBB2 HRAS PIK3CA TP53
43 medulloblastoma 11.7 APC EGFR ERBB2 HOTAIR NRAS PIK3CA
44 uterine carcinosarcoma 11.7 EGFR ERBB2 HRAS PIK3CA TP53
45 suppression of tumorigenicity 12 11.7 BRAF HRAS PIK3CA SMAD4 TP53
46 bladder squamous cell carcinoma 11.7 BRAF ERBB2 FGFR3 PIK3CA TP53
47 differentiated thyroid carcinoma 11.7 BRAF EGFR HRAS NRAS TP53
48 transitional cell carcinoma 11.7 EGFR ERBB2 FGFR3 HRAS TP53
49 breast squamous cell carcinoma 11.7 EGFR ERBB2 PIK3CA TP53
50 esophagus adenocarcinoma 11.6 ERBB2 PIK3CA SMAD4 TP53

Graphical network of the top 20 diseases related to Lung Cancer Susceptibility 3:



Diseases related to Lung Cancer Susceptibility 3

Symptoms & Phenotypes for Lung Cancer Susceptibility 3

Clinical features from OMIM:

612571

GenomeRNAi Phenotypes related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.31 EGFR PIK3CA BRAF HRAS
2 Decreased viability GR00221-A-1 10.31 HRAS EGFR NRAS PIK3CA FGFR3 RAF1
3 Decreased viability GR00221-A-2 10.31 HRAS PIK3CA FGFR3 RAF1
4 Decreased viability GR00221-A-3 10.31 HRAS NRAS FGFR3
5 Decreased viability GR00221-A-4 10.31 EGFR PIK3CA BRAF
6 Decreased viability GR00231-A 10.31 RAF1
7 Decreased viability GR00301-A 10.31 BRAF RAF1
8 Decreased viability GR00381-A-1 10.31 BRAF
9 Decreased viability GR00402-S-2 10.31 HRAS EGFR NRAS PIK3CA FGFR3 BRAF
10 Decreased cell migration GR00055-A-1 9.8 CDK4 EGFR PIK3CA FGFR3 BRAF HRAS
11 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.7 EGFR NRAS ERBB2 FGFR3 APC HRAS
12 Decreased cella89culturea89derived Hepatitis C virus (HCVcc; Luca89Jc1) infection GR00234-A-2 9.43 CDK4 EGFR BRAF
13 Increased cell migration GR00055-A-3 8.92 HRAS EGFR BRAF PIK3CA

MGI Mouse Phenotypes related to Lung Cancer Susceptibility 3:

46 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.4 PRKN SMAD4 PIK3CA RAF1 TP53 APC
2 cardiovascular system MP:0005385 10.4 PRKN SMAD4 RAF1 TP53 CDK4 BRAF
3 cellular MP:0005384 10.39 PRKN PIK3CA RAF1 TP53 SMAD4 BRAF
4 growth/size/body region MP:0005378 10.39 PRKN SMAD4 PIK3CA RAF1 TP53 APC
5 homeostasis/metabolism MP:0005376 10.37 RAF1 PRKN PIK3CA TP53 SMAD4 BRAF
6 integument MP:0010771 10.36 PRKN SMAD4 RAF1 TP53 CDK4 BRAF
7 endocrine/exocrine gland MP:0005379 10.32 SMAD4 PIK3CA RAF1 TP53 CDK4 BRAF
8 mortality/aging MP:0010768 10.32 RAF1 PRKN PIK3CA TP53 SMAD4 BRAF
9 craniofacial MP:0005382 10.3 SMAD4 RAF1 TP53 BRAF APC EGFR
10 digestive/alimentary MP:0005381 10.3 SMAD4 TP53 CDK4 BRAF APC ERBB2
11 embryo MP:0005380 10.29 SMAD4 PIK3CA RAF1 TP53 APC CDK4
12 neoplasm MP:0002006 10.26 SMAD4 RAF1 TP53 CDK4 BRAF APC
13 nervous system MP:0003631 10.23 PRKN PIK3CA RAF1 TP53 SMAD4 APC
14 muscle MP:0005369 10.19 PRKN SMAD4 RAF1 TP53 CDK4 BRAF
15 normal MP:0002873 10.18 PRKN SMAD4 RAF1 TP53 CDK4 BRAF
16 liver/biliary system MP:0005370 10.13 RAF1 TP53 SMAD4 BRAF APC EGFR
17 no phenotypic analysis MP:0003012 10.09 PRKN PIK3CA RAF1 TP53 APC EGFR
18 limbs/digits/tail MP:0005371 10.08 TP53 SMAD4 APC ERBB2 EGFR FGFR3
19 hearing/vestibular/ear MP:0005377 10.04 RAF1 TP53 BRAF APC EGFR FGFR3
20 renal/urinary system MP:0005367 9.92 TP53 SMAD4 BRAF APC EGFR CDK4
21 reproductive system MP:0005389 9.91 PIK3CA TP53 SMAD4 BRAF APC CDK4
22 pigmentation MP:0001186 9.85 TP53 APC BRAF EGFR CDK4 NRAS
23 respiratory system MP:0005388 9.76 RAF1 PRKN TP53 BRAF ERBB2 EGFR
24 skeleton MP:0005390 9.73 PRKN SMAD4 RAF1 TP53 BRAF APC
25 vision/eye MP:0005391 9.28 PIK3CA RAF1 TP53 APC BRAF EGFR

Drugs & Therapeutics for Lung Cancer Susceptibility 3

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Gilotrif 18 49 AFATINIB DIMALEATE Boehringer Ingelheim July 2013

Drugs for Lung Cancer Susceptibility 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 202)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
2
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
3
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
4
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 150399-23-8, 137281-23-3 446556 60843
5
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 184475-35-2 123631
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
7
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
8 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Mitogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10
Erlotinib Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 183319-69-9 176871
11 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
16 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
17 Endostatins Phase 4 71581480
18 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 tyrosine Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
22
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
23
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
24
Mesna Approved, Investigational Phase 3,Phase 2 3375-50-6 598
25
Loperamide Approved Phase 3 53179-11-6 3955
26
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 216974-75-3
27
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
28
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
29
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
30
Hydroxocobalamin Approved Phase 3,Not Applicable 13422-51-0 11953898 44475014
31
Cetuximab Approved Phase 3,Phase 1,Phase 2 205923-56-4 56842117 2333
32
Crizotinib Approved Phase 3,Phase 2,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
33
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
34
Celecoxib Approved, Investigational Phase 3,Phase 2 169590-42-5 2662
35
Ceritinib Approved Phase 3,Phase 2 1032900-25-6
36
Xylometazoline Approved, Investigational Phase 3 526-36-3 5709
37
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
38
Cyanocobalamin Approved, Nutraceutical Phase 3,Not Applicable 68-19-9 44176380
39
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 3,Not Applicable 13422-55-4
40
Tirapazamine Investigational Phase 3,Phase 1 27314-97-2
41 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
42 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
43 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
44 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
45 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
46 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1,Not Applicable
47 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
48 Protective Agents Phase 3,Phase 2
49 Gastrointestinal Agents Phase 3
50 Antibodies Phase 2, Phase 3,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 366)
# Name Status NCT ID Phase Drugs
1 Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
2 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
3 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
4 A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
5 Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma Recruiting NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
6 Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Recruiting NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy
7 Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Not yet recruiting NCT02399566 Phase 4 Erlotinib, Pemetrexed
8 Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy Unknown status NCT01066195 Phase 3 iressa;alimta
9 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
10 First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker Completed NCT00455936 Phase 3 Gefitinib
11 Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin Completed NCT00966914 Phase 3 Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel;Placebo in combination with cisplatin and docetaxel or paclitaxel
12 BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC) Completed NCT01121393 Phase 3 Gemcitabine+Cisplatin;BIBW 2992
13 BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation Completed NCT00949650 Phase 3 Pemetrexed;BIBW 2992;Cisplatin
14 ADAM-Afatinib Diarrhea Assessment and Management Completed NCT01814553 Phase 3 afatinib;loperamide
15 Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer Completed NCT01404260 Phase 3 Gefitinib;Gemcitabine +Carboplatin
16 Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery Completed NCT00003387 Phase 3 carboplatin;chemotherapy;paclitaxel
17 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
18 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
19 Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
20 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
21 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
22 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed Completed NCT00003235 Phase 3 carboplatin;paclitaxel
23 Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer Completed NCT00003831 Phase 3
24 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
25 Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
26 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
27 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
28 Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00006484 Phase 3 carboplatin;paclitaxel;tirapazamine
29 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed NCT00003901 Phase 3
30 Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer Completed NCT00003685 Phase 3
31 Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer Completed NCT00003117 Phase 3 carboplatin;paclitaxel
32 Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
33 Adjuvant Chemotherapy for High Post-operative Recurrence Risk Stage pI Lung Adenocarcinoma Recruiting NCT03380468 Phase 2, Phase 3 cisplatin plus pemetrexed
34 Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma Recruiting NCT02518802 Phase 3 Gefitinib;Pemetrexed
35 Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas) Recruiting NCT02893332 Phase 3 TKI (Gefitinib or Tarceva )
36 Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung Adenocarcinoma Recruiting NCT02281708 Phase 3 vinorelbine plus cisplatin
37 Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma Recruiting NCT02125240 Phase 3 Icotinib;Placebo
38 To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer Recruiting NCT02974426 Phase 3 Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
39 Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer Recruiting NCT01407822 Phase 2, Phase 3 Erlotinib;Gemcitabine/cisplatin
40 Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases Recruiting NCT02162537 Phase 3 Cisplatin;Pemetrexed;Bevacizumab
41 Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Recruiting NCT02194738 Phase 3 Crizotinib;Erlotinib Hydrochloride
42 Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients Active, not recruiting NCT01719536 Phase 3 Icotinib;Chemotherapy
43 S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
44 LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Active, not recruiting NCT01828112 Phase 3 Ceritinib;pemetrexed;docetaxel
45 LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer Active, not recruiting NCT01828099 Phase 3 Ceritinib;Pemetrexed;Cisplatin;Carboplatin
46 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
47 Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT01107626 Phase 3 pemetrexed disodium
48 Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma Enrolling by invitation NCT02929693 Phase 3 gefitinib;Yiqi-yangyin-jiedu decoction;placebo
49 Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma Enrolling by invitation NCT02889692 Phase 3 YiQiFang;YangYinFang;YiQiYangYinFang;placebo granules;Erlotinib®;Gefitinib®;Icotinib®
50 Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Not yet recruiting NCT02011997 Phase 3

Search NIH Clinical Center for Lung Cancer Susceptibility 3

Cochrane evidence based reviews: adenocarcinoma of lung

Genetic Tests for Lung Cancer Susceptibility 3

Genetic tests related to Lung Cancer Susceptibility 3:

# Genetic test Affiliating Genes
1 Lung Adenocarcinoma 29

Anatomical Context for Lung Cancer Susceptibility 3

MalaCards organs/tissues related to Lung Cancer Susceptibility 3:

41
Lung, Brain, Testes, Endothelial, Lymph Node, Bone, Thyroid

Publications for Lung Cancer Susceptibility 3

Articles related to Lung Cancer Susceptibility 3:

(show top 50) (show all 2349)
# Title Authors Year
1
Effects of long noncoding RNA SPRY4-IT1-mediated EZH2 on the invasion and migration of lung adenocarcinoma. ( 28796375 )
2018
2
Are exon 19 deletions and L858R different in early stage lung adenocarcinoma? ( 29026990 )
2018
3
Ground-glass opacity heralding invasive lung adenocarcinoma with prodromal dermatomyositis: a case report. ( 29415746 )
2018
4
TIFA Promotes Cell Survival and Migration in Lung Adenocarcinoma. ( 29975933 )
2018
5
LDHA upregulation independently predicts poor survival in lung adenocarcinoma, but not in lung squamous cell carcinoma. ( 29756998 )
2018
6
Long intergenic non-protein coding RNA 319 aggravates lung adenocarcinoma carcinogenesis by modulating miR-450b-5p/EZH2. ( 29408583 )
2018
7
Diffusion-weighted magnetic resonance imaging-directed biopsy of a metastatic bone tumor: Lung adenocarcinoma with <i>ALK</i> rearrangement. ( 29977788 )
2018
8
Recurrent Pericardial Effusion While Receiving Nivolumab for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature. ( 29937384 )
2018
9
Increased circular RNA hsa_circ_0012673 acts as a sponge of miR-22 to promote lung adenocarcinoma proliferation. ( 29366790 )
2018
10
MID1-PP2A complex functions as new insights in human lung adenocarcinoma. ( 29450633 )
2018
11
High KIF2A expression promotes proliferation, migration and predicts poor prognosis in lung adenocarcinoma. ( 29427669 )
2018
12
Expression and network analysis of YBX1 interactors for identification of new drug targets in lung adenocarcinoma. ( 29973960 )
2018
13
GATA3 acetylation at K119 by CBP inhibits cell migration and invasion in lung adenocarcinoma. ( 29453984 )
2018
14
Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma. ( 29656748 )
2018
15
GATA6-positive lung adenocarcinomas are associated with invasive mucinous adenocarcinoma morphology, hepatocyte nuclear factor 4I+ expression, and KRAS mutations. ( 29469192 )
2018
16
V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics. ( 29320776 )
2018
17
Putative lung adenocarcinoma with epidermal growth factor receptor mutation presenting as carcinoma of unknown primary site: A case report. ( 29443782 )
2018
18
BRM270 inhibits cancer stem cell maintenance via microRNA regulation in chemoresistant A549 lung adenocarcinoma cells. ( 29445170 )
2018
19
Comprehensive Analysis of DNA Methylation and Gene Expression Datasets Identified MMP9 and TWIST1 as Important Pathogenic Genes of Lung Adenocarcinoma. ( 29443542 )
2018
20
Clinical Significance of Subcellular Localization of Maspin in Patients with Pathological Stage IA Lung Adenocarcinoma. ( 29715131 )
2018
21
USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma. ( 29981430 )
2018
22
Mucinous Lung Adenocarcinoma Metastasis to Testis in a 29 Year Old-A Case Report. ( 29548865 )
2018
23
E-cadherin Loss Accelerates Tumor Progression and Metastasis in a Mouse Model of Lung Adenocarcinoma. ( 29447458 )
2018
24
Downregulation of caveolin-1 increased EGFR-TKIs sensitivity in lung adenocarcinoma cell line with EGFR mutation. ( 29137977 )
2018
25
Human umbilical cord mesenchymal stem cell-derived extracellular vesicles promote lung adenocarcinoma growth by transferring miR-410. ( 29440630 )
2018
26
Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma. ( 29980786 )
2018
27
Alteration of MicroRNA Expression Profiles by Surface-Modified Gold Nanoparticles in Human Lung Adenocarcinoma Cells. ( 29442990 )
2018
28
Role of metastasis-associated lung adenocarcinoma transcript-1 (MALAT-1) in pancreatic cancer. ( 29389953 )
2018
29
<i>SLC2A5</i> promotes lung adenocarcinoma cell growth and metastasis by enhancing fructose utilization. ( 29531835 )
2018
30
Podoplanin-positive cancer-associated fibroblast recruitment within cancer stroma is associated with a higher number of singleA nucleotide variants in cancer cells in lung adenocarcinoma. ( 29511884 )
2018
31
Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing. ( 29335443 )
2018
32
Metastasis-associated lung adenocarcinoma transcript 1 as a common molecular driver in the pathogenesis of nonalcoholic steatohepatitis and chronic immune-mediated liver damage. ( 29881817 )
2018
33
Associations Between PET Textural Features and GLUT1 Expression, and the Prognostic Significance of Textural Features in Lung Adenocarcinoma. ( 29374742 )
2018
34
Repression of Smad3 by Stat3 and c-Ski/SnoN induces gefitinib resistance in lung adenocarcinoma. ( 28115165 )
2017
35
Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma. ( 28684311 )
2017
36
Long noncoding RNA TUG1 is a diagnostic factor in lung adenocarcinoma and suppresses apoptosis via epigenetic silencing of BAX. ( 29254212 )
2017
37
Analysis of CT features and quantitative texture analysis in patients with lung adenocarcinoma: a correlation with EGFR mutations and survival rates. ( 28258739 )
2017
38
The pseudogene-derived long noncoding RNA SFTA1P is down-regulated and suppresses cell migration and invasion in lung adenocarcinoma. ( 28231733 )
2017
39
EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression. ( 28460442 )
2017
40
Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation. ( 28289161 )
2017
41
Ubiquitin-specific protease 8 is a novel prognostic marker in early-stage lung adenocarcinoma. ( 28544031 )
2017
42
A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib. ( 27613527 )
2017
43
Stathmin overexpression is associated with growth, invasion and metastasis of lung adenocarcinoma. ( 27494889 )
2017
44
CDCA2 promotes lung adenocarcinoma cell proliferation and predicts poor survival in lung adenocarcinoma patients. ( 28423619 )
2017
45
WIP promotes in-vitro invasion ability, anchorage independent growth and EMT progression of A549 lung adenocarcinoma cells by regulating RhoA levels. ( 27939884 )
2017
46
Activation of Focal Adhesion Kinase and Src Mediates Acquired Sorafenib Resistance in A549 Human Lung Adenocarcinoma Xenografts. ( 29021381 )
2017
47
Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma. ( 28481029 )
2017
48
Sex-specific incidence of EGFR mutation and its association with age and obesity in lung adenocarcinomas: a retrospective analysis. ( 28689332 )
2017
49
Drug-sensitive FGFR3 mutations in lung adenocarcinoma. ( 27998968 )
2017
50
Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma. ( 28830685 )
2017

Variations for Lung Cancer Susceptibility 3

ClinVar genetic disease variations for Lung Cancer Susceptibility 3:

6
(show top 50) (show all 776)
# Gene Variation Type Significance SNP ID Assembly Location
1 PRKN NM_013988.2(PARK2): c.(8_8)_(171_171)+180544del deletion Pathogenic GRCh38 Chromosome 6, 162262766: 162727661
2 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
3 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh38 Chromosome 18, 51065548: 51065548
4 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
5 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh38 Chromosome 18, 51067036: 51067036
6 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
7 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
8 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
9 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
10 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
11 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh38 Chromosome 17, 7674238: 7674238
12 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
13 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
14 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
15 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
16 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
17 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
18 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
19 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
20 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
21 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
22 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
23 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
24 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
25 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
26 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
27 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
28 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
29 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
30 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
31 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
32 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
33 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
34 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
35 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
36 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
37 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
38 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh38 Chromosome 11, 533467: 533467
39 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
40 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
41 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh37 Chromosome 11, 533467: 533467
42 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh37 Chromosome 11, 533466: 533466
43 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh38 Chromosome 11, 533466: 533466
44 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
45 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
46 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
47 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
48 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
49 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
50 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304

Cosmic variations for Lung Cancer Susceptibility 3:

9
(show top 50) (show all 13375)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6926570 ZRSR2 lung,NS,carcinoma,adenocarcinoma c.937+1G>T p.? 23:15820317-15820317 23
2 COSM48854 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 23
3 COSM48853 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 3:50342996-50342996 23
4 COSM95558 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 23
5 COSM6145051 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.562G>T p.A188S 16:72959584-72959584 23
6 COSM6978013 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1855C>G p.H619D 16:72958291-72958291 23
7 COSM6975161 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5985C>G p.I1995M 16:72796697-72796697 23
8 COSM6932802 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2842G>T p.A948S 16:72950843-72950843 23
9 COSM6954614 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6293C>T p.S2098L 16:72796389-72796389 23
10 COSM6967535 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3070G>T p.A1024S 16:72950615-72950615 23
11 COSM6933870 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3763C>T p.P1255S 16:72811678-72811678 23
12 COSM6926444 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10766C>G p.S3589C 16:72787510-72787510 23
13 COSM6933260 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.256G>T p.A86S 16:72959890-72959890 23
14 COSM6950021 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2135G>T p.R712L 16:72958011-72958011 23
15 COSM6965155 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.331G>A p.E111K 16:72959815-72959815 23
16 COSM6972801 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2680G>T p.D894Y 16:72957466-72957466 23
17 COSM6982281 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2701G>A p.A901T 16:72957445-72957445 23
18 COSM6937412 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1775A>C p.D592A 16:72958371-72958371 23
19 COSM6969901 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10802C>T p.S3601L 16:72787474-72787474 23
20 COSM6964729 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5670G>C p.Q1890H 16:72797012-72797012 23
21 COSM6931279 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1530G>T p.E510D 16:72958616-72958616 23
22 COSM6935718 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10628C>A p.A3543D 16:72787648-72787648 23
23 COSM6929247 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8677G>C p.G2893R 16:72794005-72794005 23
24 COSM6945078 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2755G>T p.G919C 16:72950930-72950930 23
25 COSM6935881 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1352G>T p.C451F 16:72958794-72958794 23
26 COSM6940635 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6289T>G p.F2097V 16:72796393-72796393 23
27 COSM6969446 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.628G>T p.G210C 16:72959518-72959518 23
28 COSM6968693 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 23
29 COSM6926443 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10885C>G p.P3629A 16:72787391-72787391 23
30 COSM6962405 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10961C>T p.S3654L 16:72787315-72787315 23
31 COSM6970007 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 23
32 COSM6977567 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.4834G>C p.E1612Q 16:72797848-72797848 23
33 COSM5796563 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.445C>T p.Q149* 16:72959701-72959701 23
34 COSM6966467 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5788T>C p.S1930P 16:72796894-72796894 23
35 COSM6970295 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1910G>A p.G637E 16:72958236-72958236 23
36 COSM6968715 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8982C>G p.F2994L 16:72793700-72793700 23
37 COSM6982440 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1582C>T p.Q528* 16:72958564-72958564 23
38 COSM6983995 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7133C>G p.T2378S 16:72795549-72795549 23
39 COSM6962938 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.4181C>A p.S1394* 16:72798501-72798501 23
40 COSM6937443 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 23
41 COSM6953061 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10994A>T p.D3665V 16:72787282-72787282 23
42 COSM6953714 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3431G>T p.C1144F 16:72889748-72889748 23
43 COSM6969956 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.527G>T p.G176V 16:72959619-72959619 23
44 COSM4062722 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2486T>C p.M829T 16:72957660-72957660 23
45 COSM6939807 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1408G>T p.E470* 16:72958738-72958738 23
46 COSM6956103 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2437A>T p.T813S 16:72957709-72957709 23
47 COSM6826441 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 23
48 COSM48850 ZAP70 lung,NS,carcinoma,adenocarcinoma c.1484C>T p.A495V 2:97737758-97737758 23
49 COSM95551 YWHAE lung,NS,carcinoma,adenocarcinoma c.146A>G p.Y49C 17:1364977-1364977 23
50 COSM49006 YES1 lung,NS,carcinoma,adenocarcinoma c.371+1G>T p.? 18:751704-751704 23

Copy number variations for Lung Cancer Susceptibility 3 from CNVD:

7 (show top 50) (show all 580)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13394 1 1 2300000 Gain Lung adenocarcinoma
2 13409 1 1 2300000 Gain Lung adenocarcinoma
3 13970 1 102000000 107000000 Loss Lung adenocarcinoma
4 13986 1 102200000 107200000 Loss Lung adenocarcinoma
5 14528 1 109314358 109386258 Deletion WDR47 Lung adenocarcinoma
6 15384 1 115048600 115061038 Copy number NRAS Lung adenocarcinoma
7 17560 1 143480000 149410000 Amplification ARNT Lung adenocarcinoma
8 18143 1 144218994 144222801 Amplification RBM8A Lung adenocarcinoma
9 18161 1 144227739 144235088 Amplification PEX11B Lung adenocarcinoma
10 18176 1 144287344 144297903 Amplification PIAS3 Lung adenocarcinoma
11 18223 1 144475951 145932379 Amplification GPR89A Lung adenocarcinoma
12 18385 1 145180914 145234067 Amplification CHD1L Lung adenocarcinoma
13 18405 1 145479805 145564639 Amplification BCL9 Lung adenocarcinoma
14 18433 1 145585791 145609258 Amplification ACP6 Lung adenocarcinoma
15 19003 1 148137824 148138969 Amplification BOLA1 Lung adenocarcinoma
16 19039 1 148305965 148384129 Amplification VPS45 Lung adenocarcinoma
17 19152 1 148885329 148936257 Amplification GOLPH3L Lung adenocarcinoma
18 19199 1 149165511 149203837 Amplification SETDB1 Lung adenocarcinoma
19 19207 1 149221122 149234738 Amplification ANXA9 Lung adenocarcinoma
20 19214 1 149247596 149274813 Amplification PRUNE Lung adenocarcinoma
21 19280 1 149399337 149404960 Amplification LYSMD1 Lung adenocarcinoma
22 19287 1 149415557 149429264 Amplification VPS72 Lung adenocarcinoma
23 19299 1 149493820 149506578 Amplification PSMD4 Lung adenocarcinoma
24 19341 1 149638664 149641036 Amplification PSMB4 Lung adenocarcinoma
25 19375 1 149998746 150002664 Amplification MRPL9 Lung adenocarcinoma
26 19378 1 150009206 150029634 Amplification TDRKH Lung adenocarcinoma
27 19432 1 150271605 150276135 Amplification S100A11 Lung adenocarcinoma
28 20047 1 152787674 152797744 Amplification UBE2Q1 Lung adenocarcinoma
29 20052 1 152821157 152867061 Amplification ADAR Lung adenocarcinoma
30 20569 1 153196125 153200882 Amplification PYGO2 Lung adenocarcinoma
31 20571 1 153201397 153213464 Amplification SHC1 Lung adenocarcinoma
32 20591 1 153213790 153218346 Amplification CKS1B Lung adenocarcinoma
33 20592 1 153222440 153232211 Amplification FLAD1 Lung adenocarcinoma
34 20617 1 153302836 153308653 Amplification EFNA4 Lung adenocarcinoma
35 20622 1 153317971 153326638 Amplification EFNA3 Lung adenocarcinoma
36 20838 1 154761820 154809020 Amplification IQGAP3 Lung adenocarcinoma
37 20853 1 154828181 154830715 Amplification APOA1BP Lung adenocarcinoma
38 20863 1 154936029 154941999 Amplification CRABP2 Lung adenocarcinoma
39 20868 1 154959036 154964835 Amplification ISG20L2 Lung adenocarcinoma
40 20872 1 154973717 154977547 Amplification MRPL24 Lung adenocarcinoma
41 20875 1 154978522 155003341 Amplification HDGF Lung adenocarcinoma
42 20983 1 155749790 155788934 Amplification FCRL5 Lung adenocarcinoma
43 21047 1 156490550 156494682 Amplification CD1A Lung adenocarcinoma
44 21335 1 158163454 158182010 Amplification IGSF9 Lung adenocarcinoma
45 21364 1 158264085 158268407 Amplification PIGM Lung adenocarcinoma
46 21422 1 158525000 158579978 Amplification COPA Lung adenocarcinoma
47 21516 1 159308119 159325966 Amplification PVRL4 Lung adenocarcinoma
48 21522 1 159336969 159354490 Amplification PFDN2 Lung adenocarcinoma
49 21527 1 159354514 159361857 Amplification NIT1 Lung adenocarcinoma
50 21533 1 159390157 159395270 Amplification UFC1 Lung adenocarcinoma

Expression for Lung Cancer Susceptibility 3

LifeMap Discovery
Genes differentially expressed in tissues of Lung Cancer Susceptibility 3 patients vs. healthy controls: 35 (show all 45)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 TNNC1 troponin C type 1 (slow) Lung - 5.28 0.000
2 COL11A1 collagen, type XI, alpha 1 Lung + 5.07 0.000
3 MMP1 matrix metallopeptidase 1 Lung + 4.75 0.000
4 AGER advanced glycosylation end product-specific receptor Lung - 4.69 0.000
5 WIF1 WNT inhibitory factor 1 Lung - 4.60 0.000
6 SOSTDC1 sclerostin domain containing 1 Lung - 4.47 0.000
7 FABP4 fatty acid binding protein 4, adipocyte Lung - 4.32 0.000
8 CDH3 cadherin 3, type 1, P-cadherin (placental) Lung + 4.31 0.000
9 FOSB FBJ murine osteosarcoma viral oncogene homolog B Lung - 4.24 0.000
10 TMEM100 transmembrane protein 100 Lung - 4.20 0.000
11 CLEC3B C-type lectin domain family 3, member B Lung - 4.18 0.000
12 FCN3 ficolin (collagen/fibrinogen domain containing) 3 Lung - 4.17 0.000
13 MT1M metallothionein 1M Lung - 4.07 0.000
14 SPP1 secreted phosphoprotein 1 Lung + 4.04 0.000
15 SPINK1 serine peptidase inhibitor, Kazal type 1 Lung + 3.96 0.000
16 COL10A1 collagen, type X, alpha 1 Lung + 3.79 0.000
17 CLIC5 chloride intracellular channel 5 Lung - 3.65 0.000
18 ADIRF adipogenesis regulatory factor Lung - 3.65 0.000
19 RAMP2 receptor (G protein-coupled) activity modifying protein 2 Lung - 3.62 0.000
20 HIGD1B HIG1 hypoxia inducible domain family, member 1B Lung - 3.60 0.000
21 STXBP6 syntaxin binding protein 6 (amisyn) Lung - 3.59 0.000
22 TMPRSS4 transmembrane protease, serine 4 Lung + 3.53 0.000
23 EFCC1 EF-hand and coiled-coil domain containing 1 Lung - 3.47 0.000
24 MFAP4 microfibrillar-associated protein 4 Lung - 3.47 0.000
25 ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 Lung + 3.47 0.000
26 TOP2A topoisomerase (DNA) II alpha Lung + 3.41 0.000
27 TCF21 transcription factor 21 Lung - 3.38 0.000
28 CA4 carbonic anhydrase IV Lung - 3.38 0.000
29 CYP4B1 cytochrome P450, family 4, subfamily B, polypeptide 1 Lung - 3.33 0.000
30 GPM6A glycoprotein M6A Lung - 3.30 0.000
31 GINS2 GINS complex subunit 2 (Psf2 homolog) Lung + 3.29 0.000
32 NEK2 NIMA-related kinase 2 Lung + 3.27 0.000
33 TOX3 TOX high mobility group box family member 3 Lung + 3.24 0.000
34 IL1RL1 interleukin 1 receptor-like 1 Lung - 3.21 0.000
35 PKNOX2 PBX/knotted 1 homeobox 2 Lung - 3.21 0.000
36 ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 Lung - 3.17 0.000
37 SCGB1A1 secretoglobin, family 1A, member 1 (uteroglobin) Lung - 3.17 0.000
38 FIGF c-fos induced growth factor (vascular endothelial growth factor D) Lung - 3.14 0.000
39 CRABP2 cellular retinoic acid binding protein 2 Lung + 3.11 0.000
40 SGCG sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) Lung - 3.10 0.000
41 ADAMTS8 ADAM metallopeptidase with thrombospondin type 1 motif, 8 Lung - 3.08 0.000
42 SFTPD surfactant protein D Lung - 3.07 0.000
43 MARCO macrophage receptor with collagenous structure Lung - 3.07 0.000
44 COL1A1 collagen, type I, alpha 1 Lung + 3.05 0.000
45 NMU neuromedin U Lung + 3.05 0.000
Search GEO for disease gene expression data for Lung Cancer Susceptibility 3.

Pathways for Lung Cancer Susceptibility 3

Pathways related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show top 50) (show all 145)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 APC BRAF CDK4 EGFR ERBB2 FGFR3
2
Show member pathways
13.86 BRAF CDK4 EGFR ERBB2 FGFR3 HRAS
3
Show member pathways
13.85 APC BRAF EGFR ERBB2 FGFR3 HRAS
4
Show member pathways
13.79 BRAF EGFR ERBB2 FGFR3 HRAS NRAS
5
Show member pathways
13.66 BRAF EGFR ERBB2 FGFR3 HRAS NRAS
6
Show member pathways
13.64 BRAF EGFR ERBB2 FGFR3 HRAS NRAS
7
Show member pathways
13.62 BRAF CDK4 EGFR ERBB2 FGFR3 HRAS
8
Show member pathways
13.59 EGFR ERBB2 FGFR3 HRAS NRAS PIK3CA
9
Show member pathways
13.5 BRAF EGFR ERBB2 FGFR3 HRAS NRAS
10
Show member pathways
13.41 APC BRAF EGFR ERBB2 FGFR3 HRAS
11
Show member pathways
13.2 BRAF EGFR FGFR3 HRAS NRAS RAF1
12
Show member pathways
13.16 APC BRAF CDK4 EGFR HRAS NRAS
13
Show member pathways
13.12 APC CDK4 EGFR ERBB2 FGFR3 HRAS
14
Show member pathways
13.07 BRAF EGFR HRAS NRAS PIK3CA RAF1
15
Show member pathways
13.05 BRAF EGFR ERBB2 HRAS NRAS PIK3CA
16
Show member pathways
13.04 BRAF EGFR ERBB2 HRAS NRAS PIK3CA
17
Show member pathways
13.01 BRAF EGFR ERBB2 FGFR3 HRAS NRAS
18
Show member pathways
12.96 APC BRAF CDK4 EGFR ERBB2 HRAS
19
Show member pathways
12.93 BRAF HRAS NRAS PIK3CA RAF1
20
Show member pathways
12.93 BRAF EGFR ERBB2 HRAS NRAS RAF1
21
Show member pathways
12.91 HRAS NRAS PIK3CA RAF1 TP53
22 12.9 BRAF EGFR ERBB2 FGFR3 HRAS NRAS
23
Show member pathways
12.88 BRAF EGFR FGFR3 HRAS NRAS PIK3CA
24
Show member pathways
12.87 EGFR ERBB2 FGFR3 HRAS NRAS PIK3CA
25
Show member pathways
12.86 BRAF CDK4 EGFR ERBB2 FGFR3 HRAS
26
Show member pathways
12.85 APC BRAF ERBB2 HRAS NRAS PIK3CA
27
Show member pathways
12.84 BRAF EGFR HRAS NRAS RAF1
28
Show member pathways
12.81 BRAF EGFR HRAS NRAS RAF1 TP53
29
Show member pathways
12.81 APC BRAF CDK4 EGFR ERBB2 HRAS
30
Show member pathways
12.79 BRAF EGFR HRAS NRAS RAF1
31
Show member pathways
12.78 EGFR HRAS NRAS PIK3CA RAF1
32 12.76 APC BRAF EGFR FGFR3 HRAS NRAS
33 12.76 APC BRAF CDK4 EGFR ERBB2 FGFR3
34
Show member pathways
12.74 EGFR ERBB2 HRAS NRAS PIK3CA TP53
35
Show member pathways
12.72 CDK4 HRAS NRAS PIK3CA RAF1 SMAD4
36
Show member pathways
12.7 BRAF FGFR3 HRAS NRAS PIK3CA
37
Show member pathways
12.66 BRAF HRAS NRAS PIK3CA RAF1
38
Show member pathways
12.66 BRAF EGFR ERBB2 HRAS NRAS PIK3CA
39
Show member pathways
12.63 BRAF EGFR ERBB2 HRAS NRAS PIK3CA
40
Show member pathways
12.62 ERBB2 HRAS NRAS PIK3CA RAF1
41
Show member pathways
12.59 FGFR3 HRAS NRAS PIK3CA RAF1
42
Show member pathways
12.59 EGFR ERBB2 FGFR3 HRAS NRAS PIK3CA
43
Show member pathways
12.58 CDK4 HRAS NRAS PIK3CA RAF1
44 12.57 APC CDK4 HRAS NRAS PIK3CA SMAD4
45
Show member pathways
12.56 EGFR HRAS NRAS PIK3CA RAF1
46
Show member pathways
12.55 EGFR HRAS NRAS PIK3CA RAF1
47 12.54 APC EGFR ERBB2 FGFR3 HRAS MIR375
48
Show member pathways
12.53 BRAF HRAS NRAS RAF1
49
Show member pathways
12.53 HRAS PIK3CA RAF1 TP53
50
Show member pathways
12.53 BRAF HRAS NRAS PIK3CA RAF1

GO Terms for Lung Cancer Susceptibility 3

Cellular components related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.1 APC CDK4 EGFR ERBB2 HRAS PRKN

Biological processes related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 BRAF ERBB2 HRAS PRKN TP53
2 protein phosphorylation GO:0006468 9.95 BRAF CDK4 EGFR ERBB2 FGFR3 PIK3CA
3 regulation of cell proliferation GO:0042127 9.94 BRAF CDK4 EGFR SMAD4
4 axon guidance GO:0007411 9.9 HRAS NRAS PIK3CA SMAD4
5 positive regulation of protein phosphorylation GO:0001934 9.86 EGFR ERBB2 HRAS RAF1
6 positive regulation of protein kinase B signaling GO:0051897 9.85 EGFR ERBB2 FGFR3 PIK3CA
7 positive regulation of MAPK cascade GO:0043410 9.84 EGFR ERBB2 FGFR3 HRAS
8 wound healing GO:0042060 9.82 EGFR ERBB2 RAF1
9 negative regulation of neuron apoptotic process GO:0043524 9.81 BRAF HRAS PIK3CA PRKN
10 Ras protein signal transduction GO:0007265 9.8 HRAS NRAS TP53
11 positive regulation of kinase activity GO:0033674 9.8 EGFR ERBB2 FGFR3
12 cellular response to drug GO:0035690 9.79 BRAF EGFR TP53
13 somatic stem cell population maintenance GO:0035019 9.78 BRAF RAF1 SMAD4
14 phosphatidylinositol phosphorylation GO:0046854 9.78 EGFR ERBB2 FGFR3 PIK3CA
15 positive regulation of MAP kinase activity GO:0043406 9.77 EGFR ERBB2 HRAS
16 positive regulation of epithelial cell proliferation GO:0050679 9.76 EGFR ERBB2 HRAS
17 activation of MAPKK activity GO:0000186 9.74 BRAF EGFR RAF1
18 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.73 BRAF EGFR PIK3CA RAF1
19 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.73 BRAF EGFR ERBB2 FGFR3 HRAS RAF1
20 negative regulation of signal transduction GO:0009968 9.72 BRAF EGFR ERBB2 FGFR3 RAF1
21 cell proliferation GO:0008283 9.7 APC EGFR ERBB2 HRAS RAF1 SMAD4
22 regulation of cell motility GO:2000145 9.67 EGFR ERBB2 RAF1
23 epidermal growth factor receptor signaling pathway GO:0007173 9.67 EGFR HRAS NRAS PIK3CA
24 regulation of microtubule-based process GO:0032886 9.63 APC ERBB2
25 MAPK cascade GO:0000165 9.5 BRAF EGFR ERBB2 FGFR3 HRAS NRAS
26 ERBB2 signaling pathway GO:0038128 9.02 EGFR ERBB2 HRAS NRAS PIK3CA
27 intracellular signal transduction GO:0035556 10.04 BRAF EGFR ERBB2 RAF1 SMAD4
28 negative regulation of cell proliferation GO:0008285 10.01 APC HRAS RAF1 SMAD4 TP53
29 negative regulation of apoptotic process GO:0043066 10 BRAF EGFR ERBB2 FGFR3 RAF1 TP53
30 phosphorylation GO:0016310 10 BRAF CDK4 EGFR ERBB2 FGFR3 PIK3CA

Molecular functions related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.91 BRAF EGFR ERBB2 RAF1 SMAD4 TP53
2 kinase activity GO:0016301 9.91 BRAF CDK4 EGFR ERBB2 FGFR3 PIK3CA
3 identical protein binding GO:0042802 9.91 APC BRAF EGFR ERBB2 FGFR3 PRKN
4 protein kinase activity GO:0004672 9.88 BRAF CDK4 EGFR ERBB2 FGFR3 RAF1
5 protein phosphatase binding GO:0019903 9.67 EGFR ERBB2 TP53
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.65 EGFR ERBB2 FGFR3
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.62 EGFR ERBB2 FGFR3 PIK3CA
8 MAP kinase kinase kinase activity GO:0004709 9.55 BRAF EGFR ERBB2 FGFR3 RAF1
9 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.51 EGFR ERBB2
10 mitogen-activated protein kinase kinase binding GO:0031434 9.35 BRAF EGFR ERBB2 FGFR3 RAF1
11 nucleotide binding GO:0000166 9.23 BRAF CDK4 EGFR ERBB2 FGFR3 HRAS
12 transferase activity GO:0016740 10.13 BRAF CDK4 EGFR ERBB2 FGFR3 PIK3CA
13 ATP binding GO:0005524 10.06 BRAF CDK4 EGFR ERBB2 FGFR3 PIK3CA

Sources for Lung Cancer Susceptibility 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI